Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Cancer Discov. 2021 May 12;11(11):2868–2883. doi: 10.1158/2159-8290.CD-20-1793

Figure 1.

Figure 1.

Expression of EVI1 in inv(3)/t(3;3) AML is reversible.

A. Flow cytometric analysis of CD34- and CD15-stained inv(3;3) primary AML cells (AML-1) (left) and intracellular EVI1 staining in the gated fractions (right).

B. Flow cytometric analysis of MUTZ3 cells stained with CD34 and CD15 (left) and intracellular EVI1 staining in the gated fractions (right).

C. Bar plot showing relative expression of EVI1 in Transcripts Per Million (TPM) in sorted fractions of MUTZ3 cells. Error bars represent standard deviation of two biological replicates.